fosamprenavir has been researched along with dihydroergotamine in 1 studies
Studies (fosamprenavir) | Trials (fosamprenavir) | Recent Studies (post-2010) (fosamprenavir) | Studies (dihydroergotamine) | Trials (dihydroergotamine) | Recent Studies (post-2010) (dihydroergotamine) |
---|---|---|---|---|---|
174 | 55 | 37 | 1,450 | 241 | 116 |
Protein | Taxonomy | fosamprenavir (IC50) | dihydroergotamine (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.09 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 3.9996 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.001 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.0089 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0039 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.01 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0007 | |
D(1A) dopamine receptor | Homo sapiens (human) | 2.395 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.029 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.008 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.09 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0007 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.0053 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0068 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0032 | |
Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.8 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for fosamprenavir and dihydroergotamine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |